JP6952888B2 - 抗ｐａｃａｐ抗体 - Google Patents

抗ｐａｃａｐ抗体 Download PDF

Info

Publication number
JP6952888B2
JP6952888B2 JP2020517489A JP2020517489A JP6952888B2 JP 6952888 B2 JP6952888 B2 JP 6952888B2 JP 2020517489 A JP2020517489 A JP 2020517489A JP 2020517489 A JP2020517489 A JP 2020517489A JP 6952888 B2 JP6952888 B2 JP 6952888B2
Authority
JP
Japan
Prior art keywords
residue
antibody
alanine
threonine
phenylalanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020517489A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535167A (ja
JP2020535167A5 (https=
Inventor
キャサリン・ブローティガム・バイドラー
マイケル・プラビン・ジョンソン
チェタンクマール・ナトヴァルラル・パテル
Original Assignee
イーライ リリー アンド カンパニー
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー, イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2020535167A publication Critical patent/JP2020535167A/ja
Publication of JP2020535167A5 publication Critical patent/JP2020535167A5/ja
Priority to JP2021157701A priority Critical patent/JP7221352B2/ja
Application granted granted Critical
Publication of JP6952888B2 publication Critical patent/JP6952888B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020517489A 2017-09-29 2018-09-20 抗ｐａｃａｐ抗体 Active JP6952888B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021157701A JP7221352B2 (ja) 2017-09-29 2021-09-28 抗ｐａｃａｐ抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762565278P 2017-09-29 2017-09-29
US62/565,278 2017-09-29
PCT/US2018/051898 WO2019067293A1 (en) 2017-09-29 2018-09-20 ANTI-PACAP ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021157701A Division JP7221352B2 (ja) 2017-09-29 2021-09-28 抗ｐａｃａｐ抗体

Publications (3)

Publication Number Publication Date
JP2020535167A JP2020535167A (ja) 2020-12-03
JP2020535167A5 JP2020535167A5 (https=) 2021-01-21
JP6952888B2 true JP6952888B2 (ja) 2021-10-27

Family

ID=63794713

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020517489A Active JP6952888B2 (ja) 2017-09-29 2018-09-20 抗ｐａｃａｐ抗体
JP2021157701A Active JP7221352B2 (ja) 2017-09-29 2021-09-28 抗ｐａｃａｐ抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021157701A Active JP7221352B2 (ja) 2017-09-29 2021-09-28 抗ｐａｃａｐ抗体

Country Status (27)

Country Link
US (3) US10519225B2 (https=)
EP (1) EP3688035A1 (https=)
JP (2) JP6952888B2 (https=)
KR (1) KR102453573B1 (https=)
CN (1) CN111164105B (https=)
AR (1) AR113022A1 (https=)
AU (1) AU2018341959B2 (https=)
BR (1) BR112020003628A2 (https=)
CA (1) CA3077304C (https=)
CL (1) CL2020000705A1 (https=)
CO (1) CO2020002170A2 (https=)
CR (1) CR20200127A (https=)
DO (1) DOP2020000060A (https=)
EA (1) EA202090563A1 (https=)
EC (1) ECSP20020293A (https=)
IL (1) IL273529A (https=)
JO (1) JOP20200069A1 (https=)
MA (1) MA50654A (https=)
MX (1) MX2020003563A (https=)
MY (1) MY199876A (https=)
NZ (1) NZ762312A (https=)
PE (1) PE20201494A1 (https=)
PH (1) PH12020550340A1 (https=)
SG (1) SG11202002572YA (https=)
TW (1) TWI701260B (https=)
WO (1) WO2019067293A1 (https=)
ZA (1) ZA202001058B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2982861A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
EP3426288A4 (en) 2016-04-15 2019-10-30 Alder Biopharmaceuticals, Inc. ANTI-PACAP ANTIBODIES AND USES THEREOF
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
WO2023010065A2 (en) * 2021-07-29 2023-02-02 Cephalon Llc Compositions and methods for anti-pacap antibodies
CN117916259A (zh) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 特异性结合cgrp和pacap的抗原结合分子及其医药用途
KR102839881B1 (ko) * 2021-11-19 2025-07-31 대한민국 방송통신기자재 성능 측정 시스템 및 그 방법
WO2024218541A1 (en) * 2023-04-20 2024-10-24 Mark Hasleton Treatment of migraine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486472A (en) 1990-03-17 1996-01-23 Takeda Chemical Industries, Ltd. Monoclonal antibodies to PACAP
US6037321A (en) 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
FR2826747B1 (fr) 2001-07-02 2005-02-25 Gemplus Card Int Procede et dispositif de traitement de donnees pour la personnalisation d'une application sur un dispositif communicant portatif, par exemple une carte a puce
US7615219B2 (en) 2003-01-16 2009-11-10 Life Sciences Research Partners Vzw Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia
WO2012106407A2 (en) 2011-02-01 2012-08-09 The University Of Vermont And State Agricultural College Diagnostic and therapeutic methods and products related to anxiety disorders
JP6064861B2 (ja) 2013-03-05 2017-01-25 株式会社デンソー 熱電変換装置の製造方法
CA2906737C (en) * 2013-03-15 2023-08-15 Amgen Inc. Human pac1 antibodies
EP3035950A4 (en) 2013-08-14 2017-05-03 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
CA2982861A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
US10822408B2 (en) * 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
WO2017142961A1 (en) 2016-02-16 2017-08-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Treatment of traumatic brain injury or stroke

Also Published As

Publication number Publication date
BR112020003628A2 (pt) 2020-09-01
CO2020002170A2 (es) 2020-04-01
ZA202001058B (en) 2022-06-29
PE20201494A1 (es) 2020-12-29
CN111164105A (zh) 2020-05-15
AU2018341959A1 (en) 2020-03-05
CA3077304A1 (en) 2019-04-04
TWI701260B (zh) 2020-08-11
US10954292B2 (en) 2021-03-23
JP7221352B2 (ja) 2023-02-13
CA3077304C (en) 2023-08-01
US20200131256A1 (en) 2020-04-30
US10519225B2 (en) 2019-12-31
JOP20200069A1 (ar) 2020-04-28
JP2020535167A (ja) 2020-12-03
SG11202002572YA (en) 2020-04-29
KR20200040881A (ko) 2020-04-20
JP2022000049A (ja) 2022-01-04
MA50654A (fr) 2020-08-05
CR20200127A (es) 2020-04-08
US20190100579A1 (en) 2019-04-04
ECSP20020293A (es) 2020-06-30
IL273529A (en) 2020-05-31
PH12020550340A1 (en) 2022-05-02
MY199876A (en) 2023-11-27
NZ762312A (en) 2022-11-25
EA202090563A1 (ru) 2020-06-24
AR113022A1 (es) 2020-01-15
CL2020000705A1 (es) 2020-09-11
EP3688035A1 (en) 2020-08-05
CN111164105B (zh) 2023-07-04
MX2020003563A (es) 2020-08-03
AU2018341959B2 (en) 2021-11-25
TW201920280A (zh) 2019-06-01
DOP2020000060A (es) 2020-08-15
KR102453573B1 (ko) 2022-10-12
WO2019067293A1 (en) 2019-04-04
US20210171616A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
JP6952888B2 (ja) 抗ｐａｃａｐ抗体
US11472882B2 (en) Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
US10808027B2 (en) DNA molecules encoding antibodies to tau and methods of making thereof
CN112424223B (zh) 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
JP7352973B2 (ja) 二重特異性抗体及びその使用
KR102866306B1 (ko) 신경 성장 인자에 대한 단일 클론 항체, 및 이의 코딩 유전자 및 용도
JP2020504171A (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
US10428140B2 (en) Anti-EphA4 antibody
CN116133684B (zh) 抗人nr1抗体衍生物
JP7017641B2 (ja) 抗ＴｒｋＡ抗体
CN105085679B (zh) 全人源抗rankl抗体
RU2716101C2 (ru) Антитело к склеростину, его антигенсвязывающий фрагмент и медицинское применение
EP3990488A1 (en) Semaphorin 3a antibodies and uses thereof
JP2023534779A (ja) 抗セラミド抗体
KR20230004659A (ko) 항-인간 신경 성장 인자 항체
JP6529602B2 (ja) 抗ｃｄ２０／抗ｂａｆｆ二重特異性抗体
JP2025094941A (ja) Ｌａｇ－３アゴニスト抗体
EA040300B1 (ru) Анти-pacap антитело
KR20240022546A (ko) 항il-36r 항체 및 그의 사용
JP2025539796A (ja) Ｌａｇ－３およびｐｄ－１／ｌａｇ－３抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210907

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210928

R150 Certificate of patent or registration of utility model

Ref document number: 6952888

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250